The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

Frosted branch angiitis is a rare condition that makes the blood vessels that supply the retina look like the frosted ...

Eylea HD results were consistent across patients with branch RVOs and those with central retinal or hemiretinal vein occlusions. In the past three months, shares of REGN have plunged 35.7% compare ...

All currently FDA-approved anti-VEGF therapies for retinal vein occlusion require monthly dosing. The company said these data will be submitted to regulatory authorities around the world ...

D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion.

including those with central, branch and hemiretinal vein occlusions. In the trial, patients treated with EYLEA HD every 8 weeks experienced non-inferior vision gains compared to those treated ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with retinal vein occlusion (RVO), including those ...

These elevated pressures can extend to ocular veins, resulting in complications such as central retinal vein occlusion (CRVO). This case report highlights a rare instance of CRVO combined with ...